ValuEngine Downgrades Oramed Pharmaceuticals (ORMP) to Sell

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Oramed Pharmaceuticals in a report on Wednesday, November 22nd.

Oramed Pharmaceuticals (ORMP) opened at $8.06 on Tuesday. Oramed Pharmaceuticals has a 1-year low of $5.82 and a 1-year high of $11.34.

Large investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its holdings in shares of Oramed Pharmaceuticals by 4.4% during the 2nd quarter. Wells Fargo & Company MN now owns 14,725 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 625 shares during the period. Virtu KCG Holdings LLC bought a new position in Oramed Pharmaceuticals during the 2nd quarter valued at about $125,000. Finally, Susquehanna International Group LLP bought a new position in Oramed Pharmaceuticals during the 3rd quarter valued at about $185,000. 2.18% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was first posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3079050/valuengine-downgrades-oramed-pharmaceuticals-ormp-to-sell.html.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Receive News & Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.